This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral
David Borquez, MD
Advertisement
Articles by David Borquez, MD
Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic
Advertisement
Latest Updated Articles
- Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic
Published: April 1st 1997 | Updated:
- Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
